Loading...
Loading...
New real‑world data from 16 studies show that Tavneos (avacopan), when combined with standard therapy for ANCA‑associated vasculitis (AAV), achieved high remission rates in adults within six months.
Results indicate that over 80% of patients reached complete disease remission, exceeding rates reported in previous clinical trials, highlighting the drug’s effectiveness in everyday clinical practice. However, about 25% of patients discontinued therapy due to side effects, with liver toxicity more pronounced among Japanese patients.
These findings underscore the importance of close monitoring for adverse effects, especially in patients with pre-existing liver conditions or those on other hepatotoxic medications. Additionally, Tavneos reduces the need for traditional corticosteroids, potentially lowering long-term complications associated with steroid therapy.
This development is significant globally, providing an effective treatment option for patients with rare and complex diseases, supporting personalized treatment plans with close monitoring of vital signs and organ functions.
Source:
